Allison David, NP
Family · Port Allen, LANPI 1437430899
Payments from drug & device makers
Across 245 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$920
- Novo Nordisk$535
- Pfizer$316
- Lilly USA, LLC$294
- GSK$259
- Abbott$224
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,732100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 77 | $920 |
| Novo Nordisk | 34 | $535 |
| Pfizer | 19 | $316 |
| Lilly USA, LLC | 18 | $294 |
| GSK | 15 | $259 |
| Abbott | 10 | $224 |
| AstraZeneca | 13 | $195 |
| Merck | 11 | $177 |
| Boehringer Ingelheim | 7 | $112 |
| Paratek Pharmaceuticals, Inc. | 5 | $84 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Phathom Pharmaceuticals, Inc. | 6 | $68 |
| Novartis | 4 | $68 |
| Lundbeck LLC | 2 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Bayer | 2 | $39 |
| Amgen | 3 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Amarin Pharma, Inc. | 2 | $31 |
| Exact Sciences | 2 | $29 |
| Dexcom, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $17 |
| Corium, LLC | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
How this compares
$3,732 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $131,930 |
| JardianceEmpagliflozin | 84 | $79,144 |
| MounjaroTirzepatide | 61 | $71,650 |
| FarxigaDapagliflozin Propanediol | 32 | $36,256 |
| EliquisApixaban | 30 | $29,938 |
| JanuviaSitagliptin Phosphate | 21 | $23,619 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $21,296 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $10,733 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $9,265 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $8,387 |
| Atorvastatin Calcium | 421 | $3,828 |
| DuleraMometasone/Formoterol | 11 | $3,655 |
| Pantoprazole Sodium | 226 | $2,389 |
| Metoprolol Succinate | 173 | $1,796 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $535 | $131,930136 claims |
| Boehringer IngelheimJardiance | $112 | $79,14484 claims |
| Lilly USA, LLCMounjaro | $294 | $71,65061 claims |
| AstraZenecaFarxiga | $195 | $36,25632 claims |
| PfizerEliquis | $316 | $29,93830 claims |
| MerckJanuvia, Dulera | $177 | $27,27432 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $259 | $19,12024 claims |
| AbbVieSynthroid | $920 | $64922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Port Allen
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.